Profile data is unavailable for this security.
About the company
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to advancing antibody complement therapeutics to treat severe autoimmune diseases. The Company is dedicated to designing and delivering monoclonal antibodies with improved selectivity and potency. The Company has initiated a Phase 2 trial of DNTH103, a potential active C1s inhibitor, in generalized Myasthenia Gravis and plans to initiate additional Phase 2 trials in other neuromuscular indications, including Multifocal Motor Neuropathy and Chronic Inflammatory Demyelinating Polyneuropathy. Its product candidate, DNTH103, is a clinical-stage, highly potent, highly selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of the C1s complement protein. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile.
- Revenue in USD (TTM)5.37m
- Net income in USD-67.09m
- Incorporated2015
- Employees53.00
- LocationDianthus Therapeutics Inc7 Times Square, 43Rd FloorNEW YORK 10036United StatesUSA
- Phone+1 (929) 999-4055
- Fax+1 (302) 655-5049
- Websitehttps://dianthustx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kezar Life Sciences Inc | 0.00 | -95.78m | 555.97m | 58.00 | -- | 0.4148 | -- | -- | -13.15 | -13.15 | 0.00 | 18.37 | 0.00 | -- | -- | 0.00 | -46.34 | -32.54 | -50.90 | -34.09 | -- | -- | -- | -4,308.11 | -- | -- | 0.0711 | -- | -- | -- | -49.28 | -- | 10.08 | -- |
| Savara Inc | 0.00 | -82.94m | 556.05m | 37.00 | -- | 2.78 | -- | -- | -0.4452 | -0.4452 | 0.00 | 1.17 | 0.00 | -- | -- | 0.00 | -39.41 | -36.86 | -41.56 | -39.54 | -- | -- | -- | -102,587.50 | -- | -- | 0.1175 | -- | -- | -- | -43.38 | -- | 15.91 | -- |
| Corvus Pharmaceuticals Inc | 0.00 | -56.83m | 559.21m | 28.00 | -- | 45.09 | -- | -- | -0.9262 | -0.9262 | 0.00 | 0.1983 | 0.00 | -- | -- | 0.00 | -102.63 | -38.31 | -199.23 | -43.34 | -- | -- | -- | -- | -- | -34.33 | 0.00 | -- | -- | -- | 34.57 | -- | -37.45 | -- |
| Tourmaline Bio Inc | 0.00 | -48.85m | 582.60m | 44.00 | -- | 1.81 | -- | -- | -1.68 | -1.68 | 0.00 | 12.52 | 0.00 | -- | -- | 0.00 | -20.37 | -- | -21.05 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
| Chromadex Corp | 91.67m | 1.49m | 582.80m | 106.00 | 403.06 | 16.88 | 250.56 | 6.36 | 0.0189 | 0.0189 | 1.21 | 0.4521 | 1.67 | 3.05 | 23.51 | 864,792.40 | 2.70 | -42.11 | 4.08 | -65.14 | 61.45 | 59.68 | 1.62 | -30.64 | 2.35 | -- | 0.0004 | -- | 15.99 | 21.50 | 70.15 | -- | -36.66 | -- |
| Immunome Inc | 10.13m | -305.35m | 586.73m | 55.00 | -- | 2.65 | -- | 57.93 | -6.06 | -6.06 | 0.1889 | 3.56 | 0.0579 | -- | -- | 184,163.60 | -174.46 | -94.54 | -212.48 | -112.66 | -- | -- | -3,014.59 | -1,403.15 | -- | -- | 0.00 | -- | -- | -- | -184.68 | -- | 29.52 | -- |
| Mineralys Therapeutics Inc | 0.00 | -153.25m | 590.26m | 28.00 | -- | 2.49 | -- | -- | -3.27 | -3.27 | 0.00 | 4.76 | 0.00 | -- | -- | 0.00 | -56.16 | -- | -61.19 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
| Stoke Therapeutics Inc | 16.74m | -105.46m | 596.94m | 110.00 | -- | 2.57 | -- | 35.65 | -2.10 | -2.10 | 0.3294 | 4.38 | 0.0628 | -- | 42.55 | 152,209.10 | -39.56 | -31.62 | -46.04 | -33.92 | -- | -- | -629.86 | -1,775.50 | -- | -- | 0.00 | -- | -29.22 | -- | -3.59 | -- | 11.56 | -- |
| Altimmune Inc | 52.00k | -103.52m | 597.35m | 59.00 | -- | 4.48 | -- | 11,487.53 | -1.55 | -1.55 | 0.0008 | 1.88 | 0.0003 | -- | 0.0798 | 881.36 | -65.84 | -39.62 | -70.44 | -42.58 | -- | -- | -199,076.90 | -1,811.89 | -- | -- | 0.00 | -- | 726.47 | -47.15 | -4.41 | -- | -45.92 | -- |
| Dianthus Therapeutics Inc | 5.37m | -67.09m | 599.93m | 53.00 | -- | 1.76 | -- | 111.80 | -2.49 | -2.49 | 0.1968 | 11.51 | 0.0196 | -- | 3.13 | 101,245.30 | -24.54 | -41.40 | -25.91 | -44.70 | -- | -- | -1,250.32 | -12,132.27 | -- | -- | 0.00 | -- | -- | -- | 43.04 | -- | -57.21 | -- |
| ORIC Pharmaceuticals Inc | 0.00 | -119.87m | 643.35m | 112.00 | -- | 2.35 | -- | -- | -1.81 | -1.81 | 0.00 | 3.88 | 0.00 | -- | -- | 0.00 | -41.59 | -33.92 | -44.71 | -35.77 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | 10.09 | -- |
| AnaptysBio Inc | 57.17m | -165.66m | 644.18m | 117.00 | -- | 7.64 | -- | 11.27 | -6.07 | -6.07 | 2.09 | 2.77 | 0.1166 | -- | 7.39 | 488,649.60 | -33.78 | -18.08 | -36.91 | -18.96 | -- | -- | -289.75 | -269.21 | -- | -- | 0.00 | -- | 66.78 | 27.97 | -27.11 | -- | -5.36 | -- |
| Adaptive Biotechnologies Corp | 177.28m | -195.24m | 644.92m | 709.00 | -- | 2.88 | -- | 3.64 | -1.34 | -1.34 | 1.21 | 1.52 | 0.2778 | 4.68 | 4.92 | 250,045.10 | -30.61 | -19.69 | -35.66 | -22.06 | 58.46 | 67.18 | -110.19 | -122.27 | 3.38 | -- | 0.3725 | -- | -8.11 | 25.06 | -12.52 | -- | 11.11 | -- |
Data as of Nov 22 2024. Currency figures normalised to Dianthus Therapeutics Inc's reporting currency: US Dollar USD
66.15%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 4.17m | 14.20% |
| Avidity Partners Management LPas of 30 Sep 2024 | 2.92m | 9.93% |
| Fairmount Funds Management LLCas of 30 Sep 2024 | 2.70m | 9.20% |
| RA Capital Management LPas of 30 Sep 2024 | 2.33m | 7.94% |
| Octagon Capital Advisors LPas of 30 Sep 2024 | 1.75m | 5.95% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 1.50m | 5.11% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 1.27m | 4.31% |
| AllianceBernstein LPas of 30 Sep 2024 | 1.02m | 3.48% |
| Janus Henderson Investors US LLCas of 30 Sep 2024 | 949.33k | 3.23% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 821.13k | 2.80% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
